AstraZeneca PLC (AZN) on Tuesday said the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended approval of camizestrant in combination with a CDK4/6 inhibitor for the treatment of adults with ER-positive, HER2-negative locally advanced or metastatic breast cancer with ESR1 mutation.
The positive opinion was based on results from the Phase III SERENA-6 trial, where the camizestrant combination reduced the risk of disease progression or death by 56% compared with standard-of-care. Median progression-free survival was 16.0 months for the camizestrant combination versus 9.2 months for standard treatment.
Camizestrant is already approved in the United Arab Emirates and Saudi Arabia for certain patients with HR-positive, HER2-negative advanced breast cancer with ESR1 mutations.
Regulatory applications for the therapy in this setting are also under review in the U.S., Japan and several other countries.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.